Fibrocell Science (NASDAQ:FCSC) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Tuesday. The brokerage presently has a $0.75 price objective on the stock. Zacks Investment Research‘s price objective would indicate a potential upside of 13.64% from the company’s previous close.
According to Zacks, “Fibrocell Science, Inc. is an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs. Fibrocell’s most advanced drug candidate, azficel-T, uses its FDA-approved proprietary autologous fibroblast technology and is in a Phase II clinical trial for the treatment of chronic dysphonia resulting from vocal cord scarring or atrophy. In collaboration with Intrexon Corporation, a leader in synthetic biology, Fibrocell is also developing gene therapies for orphan skin diseases using gene-modified autologous fibroblasts. The Company’s lead orphan gene-therapy drug candidate, FCX-007, is in late stage pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Fibrocell is also in pre-clinical development of FCX-013, its second gene-therapy drug candidate, for the treatment of linear scleroderma. “
Separately, HC Wainwright set a $6.00 price objective on Fibrocell Science and gave the company a “buy” rating in a research note on Tuesday, January 16th. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. Fibrocell Science presently has an average rating of “Buy” and an average price target of $3.94.
Fibrocell Science (NASDAQ:FCSC) last released its quarterly earnings data on Monday, November 13th. The company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.41) by $0.07. analysts anticipate that Fibrocell Science will post -1.63 earnings per share for the current fiscal year.
In related news, major shareholder Randal J. Kirk purchased 2,727,273 shares of the company’s stock in a transaction on Monday, December 11th. The stock was bought at an average price of $0.77 per share, with a total value of $2,100,000.21. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 2.10% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the business. Pura Vida Investments LLC purchased a new position in Fibrocell Science during the third quarter worth $909,000. Parametric Portfolio Associates LLC increased its position in Fibrocell Science by 264.0% during the second quarter. Parametric Portfolio Associates LLC now owns 48,259 shares of the company’s stock worth $194,000 after buying an additional 35,000 shares in the last quarter. FNY Partners Fund LP purchased a new position in Fibrocell Science during the fourth quarter worth $129,000. Finally, Third Security LLC increased its position in Fibrocell Science by 49.2% during the fourth quarter. Third Security LLC now owns 8,267,413 shares of the company’s stock worth $5,292,000 after buying an additional 2,727,273 shares in the last quarter. 43.00% of the stock is owned by institutional investors.
Fibrocell Science Company Profile
Fibrocell Science, Inc is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Fibrocell Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science and related companies with MarketBeat.com's FREE daily email newsletter.